Ehlers-Danlos syndrome (EDS) is not an autoimmune disease. It is a group of inherited connective tissue disorders caused by genetic mutations that affect how your body produces or processes collagen. While autoimmune diseases involve the immune system mistakenly attacking healthy tissue, EDS results from structural defects in connective tissue that are present from birth. The confusion is understandable, though, because the two can look remarkably similar from the outside.
Why EDS Is Genetic, Not Immune-Driven
Autoimmune diseases like rheumatoid arthritis or lupus occur when the immune system targets the body’s own cells, causing inflammation and tissue damage. EDS works through an entirely different mechanism. Mutations in at least 20 different genes disrupt the production or assembly of collagen, the protein that gives structure and strength to skin, joints, blood vessels, and organs throughout the body.
Some of these genes (COL1A1, COL3A1, COL5A1, and others) provide instructions for building collagen directly. Other genes make proteins responsible for folding or processing collagen after it’s produced. When any of these genes carry a mutation, the resulting collagen molecules can’t assemble properly, and connective tissues throughout the body are weakened. This is a structural problem baked into your DNA, not an immune system gone haywire.
A 2021 review in the Journal of Translational Autoimmunity put it plainly: there is a “paucity of evidence for an immunological mechanism for EDS.” Despite the fact that rheumatologists often treat EDS patients and the disease involves joints and soft tissue, no clearly defined role for the immune system has been established in any of the 13 recognized EDS subtypes.
Why EDS Gets Confused With Autoimmune Conditions
The symptom overlap between EDS and autoimmune diseases is significant, and it’s the main reason people end up asking this question. Joint pain is the dominant complaint in hypermobile EDS (hEDS), the most common subtype. That same symptom is also a hallmark of rheumatoid arthritis, psoriatic arthritis, and several other autoimmune conditions. People with hEDS frequently deal with chronic back pain, tendonitis, bursitis, and recurring joint subluxations or dislocations, all of which can mimic inflammatory joint disease.
Beyond joint symptoms, EDS affects nearly every system in the body because connective tissue is everywhere. Fatigue, headaches, gastrointestinal problems, and a racing heart rate upon standing (a form of dysautonomia) are all common. This constellation of widespread, seemingly unrelated symptoms looks a lot like systemic autoimmune disease to clinicians who aren’t familiar with EDS. Many patients see multiple specialists over years without anyone connecting the dots, and some are initially misdiagnosed with conditions like fibromyalgia or seronegative arthritis.
How Blood Tests Can Help Tell Them Apart
One of the clearest ways to distinguish EDS from autoimmune disease is through standard inflammatory and immune markers. In autoimmune conditions like rheumatoid arthritis or lupus, blood tests typically show elevated markers of inflammation or the presence of autoantibodies, proteins that indicate the immune system is attacking the body’s own tissues.
EDS patients generally don’t show these immune signatures. Their joint pain and tissue problems stem from mechanical instability, not immune-driven inflammation. That said, the picture isn’t perfectly clean. Some research has found that EDS patients do have elevated levels of certain complement proteins (part of the immune system’s early response cascade) in their blood, likely as a secondary response to chronic joint stress and degenerative changes rather than a primary autoimmune process. Skin cells from hEDS patients also show unusual expression of proteins linked to inflammation in other diseases. These findings hint at some immune involvement downstream, but they don’t change the fundamental classification: EDS is genetic, and autoimmune markers are not part of its diagnostic criteria.
The hEDS, POTS, and MCAS Triad
You may have encountered claims that hypermobile EDS commonly occurs alongside postural orthostatic tachycardia syndrome (POTS) and mast cell activation syndrome (MCAS), a condition where immune cells release excessive amounts of chemical signals that cause allergy-like symptoms. This proposed triad has gained significant attention online and in patient communities, and because MCAS involves immune cells, it reinforces the perception that EDS has an autoimmune component.
The scientific support for this triad is weak. A 2019 review of the available literature concluded that a common underlying mechanism connecting all three conditions has not been described. The authors noted that the proposed association largely stems from an overlapping pool of vague, subjective symptoms rather than from evidence of a shared biological pathway. That doesn’t mean individual patients can’t have more than one of these conditions, but having EDS doesn’t mean your immune system is malfunctioning.
How EDS Is Actually Diagnosed
The 2017 international classification system recognizes 13 subtypes of EDS. For 12 of those subtypes, a definitive diagnosis requires genetic testing that identifies a specific causative mutation. Hypermobile EDS is the exception: no gene has been confirmed for it yet, so diagnosis relies on clinical criteria that evaluate joint hypermobility, skin involvement, and family history.
Notably, immune markers like antinuclear antibodies (ANA) or inflammatory blood tests are not part of the EDS diagnostic framework for any subtype. When these tests are ordered for someone with suspected EDS, it’s typically to rule out autoimmune conditions that share similar symptoms, not to confirm EDS itself. If your bloodwork comes back showing elevated inflammatory markers or autoantibodies, that points toward a different diagnosis or a coexisting condition rather than EDS alone.
Living With EDS When Autoimmune Conditions Run in Your Family
Having EDS doesn’t protect you from also developing an autoimmune disease, and the reverse is true too. Because EDS patients frequently experience joint pain, fatigue, and systemic symptoms, it can be easy to attribute new or worsening symptoms to EDS when something else is also going on. If your symptoms change character, if joints become hot and swollen rather than just loose and painful, or if you develop new skin rashes, dry eyes, or unexplained fevers, those warrant separate investigation.
The distinction matters for treatment. Autoimmune diseases often respond to medications that suppress or modulate the immune system. EDS management focuses on protecting joints through physical therapy, managing pain, and preventing injuries. Treating EDS with immunosuppressants wouldn’t address the underlying collagen defect, and treating an autoimmune condition with physical therapy alone would leave damaging inflammation unchecked.